A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy — MyCIDPchoice

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Clinical Trial

Official title:
A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Status Completed

Clinical Trial Summary

The purpose of the study is to evaluate clinical efficacy of rozanolixizumab as a treatment for subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Polyradiculoneuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Clinical Trial Details

NCT number	NCT03861481
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 2
Start date	March 26, 2019
Completion date	March 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05363358` - A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Completed	`NCT03864185` - The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies	Phase 2
Active, not recruiting	`NCT05084053` - A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)	Phase 3
Completed	`NCT04051944` - A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Phase 2